Merck Statement on FDA Advisory Committee Meeting for RAGWITEK™ (Short Ragweed Pollen Allergen Extract), an Investigational Sublingual Allergy Immunotherapy Tablet
Dateline City:
WHITEHOUSE STATION, N.J.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said it was pleased with the positive discussion of RAGWITEK™ (Short Ragweed Pollen Allergen Extract) at the Allergenic Products Advisory Committee meeting of the U.S. Food and Drug Administration (FDA).
Language:
English
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Merck MRK MSD Ragweed RAGWITEK Research and Development News Corporate News Latest News Source Type: news
More News: Allergy | Allergy & Immunology | Food and Drug Administration (FDA) | Merck | Pharmaceuticals